Announced
Completed
Financials
Tags
Acquisition
Minority
Venture Capital
Completed
United States
biotechnology
Private
Friendly
cell therapy
Health Care Services
Domestic
Private Equity
Synopsis
Northpond Ventures, a science-driven venture capital firm, led a $85m Series B funding round in Kyverna Therapeutics, a cell therapy company, with participation from Westlake Village BioPartners , Vida Ventures, Gilead Sciences, RTW Investments, CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital and jVen Capital. "This financing reflects significant investor confidence in the science behind Kyverna’s cell therapies, world-class team, and commitment to bringing new therapies to patients suffering from serious autoimmune diseases," Ian Clark, Kyverna Chair of Board of Directors.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.